This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
J&J Pauses Coronavirus Vaccine Trial: ETFs That May Take a Hit
by Sweta Jaiswal, FRM
Johnson & Johnson's pausing of dosing in all clinical studies on its coronavirus vaccine candidate has increased uncertainty surrounding the coronavirus vaccine development.
JNJ Beats Q3 Earnings, Lifts Outlook: Healthcare ETFs in Focus
by Sweta Killa
Despite solid results and an upbeat view, shares of JNJ dropped as the company halted its final-phase of clinical trials for its COVID-19 vaccine candidate.
ETFs in Focus on Momenta Buyout Deal With JNJ
by Sweta Killa
A number of ETFs could be the best ways for investors to tap the opportunity arising from the Momenta buyout deal.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
JNJ Beats, Cuts View on Coronavirus: Healthcare ETFs in Focus
by Sweta Killa
Investors should closely watch the movement of the stock and keep a close eye on ETFs having double-digit allocation to this diversified drug maker post its earnings release.
Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas
by Sanghamitra Saha
Warren Buffett took positions in Biogen and Kroger. Investors who want to follow Buffett's picking of these two value stocks can also play these ETFs as well.
JNJ Beats, Ups View: Healthcare ETFs to Buy
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and outpaced revenue estimates. It also raised its guidance for the full year.
Amgen to Buy Celgene's Otezla: 5 ETF Drugs
by Sweta Killa
Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
by Sweta Killa
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
JNJ Beats, Ups Sales Growth View: Healthcare ETFs in Focus
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat and also outpaced revenue estimates. Though it raised the guidance for full-year sales growth, it tightened the earnings per share forecast.
Trump Proposes 2020 Budget: ETFs to Top & Flop
by Sweta Killa
Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.
JNJ Beats, Offers Bleak Outlook: Health Care ETFs in Focus
by Sweta Killa
Johnson & Johnson expects its sales growth to slow down this year due to pricing pressures and generic-drug competition for its pharmaceutical division. This has put healthcare ETFs in focus.
Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
by Sweta Killa
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Best & Worst ETFs of Thanksgiving Week
by Sweta Killa
The three major indices logged in their biggest losses in a Thanksgiving week since 2011. We have highlighted the best and worst performing ETFs of the Thanksgiving week.
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
Healthcare ETFs in Focus Following JNJ Q2 Results
by Sweta Killa
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.